ArticleBlood cancer journal2024

Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP).

Benjamin A Derman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.